Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q3

6523.TEDINET S100Q6BS
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥265.1bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥94.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥252.4bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥86.3bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥21.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥24.1bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥10.5bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥7.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.9bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥3.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.5bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥18.6bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥3.6bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥569.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥595.1bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥431.1bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥138.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥152.1bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥137.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥151.5bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥59.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.0bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥6.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥36.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥9.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥106m2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.332022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥156.672021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.832021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.072022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.532022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥152.822021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.342021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio24.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.5%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥13.0bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-12-31¥19.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.3bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥8.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥263.3bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥263.3bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥34.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥11.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-12-31¥18.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥12.4bn
—segment totalrevenue2021-04-01 → 2021-12-31¥250.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥250.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥35.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 934
ItemContextValueUnit
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember8000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember-106000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReportableSegmentsMember-98000000JPY
Impairment losses pl IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Impairment losses pl IFRSPrior1YTDDuration-98000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember83729000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember99175000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember80421000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember263326000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember1775000000JPY
Revenue from external customers IFRSCurrentYTDDuration265102000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember83729000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember99175000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember80421000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember263326000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember1775000000JPY
Revenue IFRSCurrentYTDDuration265102000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember19671000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember8480000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember6258000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember34410000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-12981000000JPY
Operating profit loss IFRSCurrentYTDDuration21429000000JPY
Finance income IFRSCurrentYTDDuration148000000JPY
Finance costs IFRSCurrentYTDDuration14163000000JPY
Profit loss before tax IFRSCurrentYTDDuration7414000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember7685000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember8146000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember5873000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReportableSegmentsMember21704000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReconcilingItemsMember545000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration22250000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember142000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember117000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReportableSegmentsMember259000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReconcilingItemsMember116000000JPY
Impairment losses pl IFRSCurrentYTDDuration375000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第10期第３四半期（自　2022年10月１日　至　2022年12月31日）

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass